IRLAB Therapeutics Q1 report: advancing accordingly - ABG

No material news provided in the report
IRLAB/Ipsen's discussion on mesdopetam future ongoing
Presentation today at 10:00 CET


Discussions with Ipsen on mesdopetam's future ongoing

No material news were provided in the report. During the quarter, IRLAB presented the top line data of mesdopetam in Parkinson's disease levodopa induced dyskinesia (PD-LIDs). Although the primary endpoint was not met, the company reported positive anti-dyskinetic data based on the secondary endpoint UDysRS. Together with Ipsen they are currently performing an in-depth analysis of the results, in order to decide how to move forward. IRLAB communicated that the molecule is now ready for Ph 3 development. The two companies are currently exploring the best way to ensure that mesdopetam obtains the most optimal opportunities forward. The detailed data of the Ph 2b study is expected to be presented at scientific congresses in 2023. Regarding the pirepemat Ph 2 trial, IRLAB has 36/38 active study sites and anticipates that all the clinics will be activated by June '23. Other events during the quarter include the nomination of IRL1117 as lead molecule from the P003 project. IRL1117 will be developed as a once-daily oral treatment for PD and is expected to avoid the troublesome complications caused by levodopa treatments. The company is currently working in the preclinical phase in preparation for tox studies and manufacturing activities in '24e. After the reported period, IRLAB announced that Ipsen's Universal Registration Document published on April 6 '23 contained the incorrect information that the development and commercialisation rights for mesdopetam were transferred back to IRLAB. This was incorrect and Ipsen will rectify.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/irlab-therapeutics/Equity-research/2023/5/irlab-therapeutics---q1-report-advancing-accordingly/